In addition, the deactivation of CD4 and CD8 T cells in lung tissue and the reduction of their capability to generate proinflammatory cytokines was reported in vivo for lung disorder therapy using NPs (Das et al., 2022). The gene discussed is CD8A; the disease is lung disorder.